Asif Alavi
Overview
Explore the profile of Asif Alavi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
223
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lessard S, Rimmele P, Ling H, Moran K, Vieira B, Lin Y, et al.
Sci Rep
. 2024 Oct;
14(1):24298.
PMID: 39414860
BIVV003 is a gene-edited autologous cell therapy in clinical development for the potential treatment of sickle cell disease (SCD). Hematopoietic stem cells (HSC) are genetically modified with mRNA encoding zinc...
2.
Shaw B, Jimenez-Jimenez A, Burns L, Logan B, Khimani F, Shaffer B, et al.
Transplant Cell Ther
. 2022 Dec;
29(3):208.e1-208.e6.
PMID: 36584941
The use of post-transplantation cyclophosphamide (PTCy) as graft-versus-host disease (GVHD) prophylaxis has resulted in reductions in GVHD and improved outcomes in allogeneic hematopoietic cell transplantation (HCT) using HLA-mismatched related donors....
3.
Al-Share B, Assad H, Abrams J, Deol A, Alavi A, Modi D, et al.
J Oncol
. 2022 Oct;
2022:3472324.
PMID: 36213836
Purpose: Women with locally advanced/high-risk triple-negative breast cancer treated with the current standard chemotherapy continue to have a poor prognosis. High-dose chemotherapy with autologous stem cell transplant as treatment for...
4.
Shah H, Jang H, Singh P, Kosti J, Kin A, Alavi A, et al.
Leuk Lymphoma
. 2021 Nov;
63(4):813-820.
PMID: 34781825
Utilization of novel agents such as brentuximab vedotin (BV) and check-point inhibitors (CI) has increased in patients with relapsed/refractory (r/r) classical Hodgkin Lymphoma (cHL). We conducted a retrospective study of...
5.
Albanyan O, Alkassis S, Kim S, Kin A, Alavi A, Ayash L, et al.
Hematol Oncol Stem Cell Ther
. 2021 Aug;
16(2):154-157.
PMID: 34425096
Mantle cell lymphoma is a rare subtype of non-Hodgkin's lymphoma with poor prognosis and continue to be challenging to treat. The choice of first line induction regimen remains a topic...
6.
Cutler C, Lee S, Arai S, Rotta M, Zoghi B, Lazaryan A, et al.
Blood
. 2021 Jul;
138(22):2278-2289.
PMID: 34265047
Belumosudil, an investigational oral selective inhibitor of Rho-associated coiled-coil-containing protein kinase 2 (ROCK2), reduces type 17 and follicular T helper cells via downregulation of STAT3 and enhances regulatory T cells...
7.
Shaw B, Jimenez-Jimenez A, Burns L, Logan B, Khimani F, Shaffer B, et al.
J Clin Oncol
. 2021 Apr;
39(18):1971-1982.
PMID: 33905264
Purpose: Hematopoietic cell transplantation (HCT) is curative for hematologic disorders, but outcomes are historically inferior when using HLA-mismatched donors. Despite unrelated donor registries listing > 38 million volunteers, 25%-80% of...
8.
Singh V, Jang H, Kim S, Ayash L, Alavi A, Ratanatharathorn V, et al.
Leuk Lymphoma
. 2020 Oct;
62(2):446-453.
PMID: 33043743
The use of G-CSF post allogeneic transplant has become a common practice to accelerate neutrophil engraftment. There is some controversy in its use. To further evaluate the effectiveness, we compared...
9.
Modi D, Chi J, Kim S, Ayash L, Alavi A, Kin A, et al.
Leuk Lymphoma
. 2020 Apr;
61(8):1877-1884.
PMID: 32270725
Maintenance therapy after first autologous transplant (autoSCT) improves progression-free survival (PFS) and overall survival (OS) in multiple myeloma (MM). However, efficacy of maintenance therapy after second autoSCT is unknown. We...
10.
Abdallah N, Kim S, Ayash L, Klimecki S, Ventimiglia M, Alavi A, et al.
Bone Marrow Transplant
. 2019 Nov;
55(8):1655-1657.
PMID: 31740765
No abstract available.